Gene therapy for retinitis pigmentosa

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Autosomal dominant retinitis pigmentosa (RP) is a leading cause of inherited vision loss in North America.
• Current treatments for RP are limited, necessitating novel therapeutic strategies.
• Rhodopsin gene mutations are the most frequent cause of dominant RP.

Purpose of the Study:

• To review the fundamental principles of gene therapy.
• To discuss various gene therapy modalities under investigation for dominant RP.
• To provide an overview of the evolving landscape of genetic treatments for retinal diseases.

Main Methods:

• Literature review of gene therapy concepts and applications in ophthalmology.
• Analysis of preclinical and clinical studies on gene therapy for rhodopsin-mediated RP.
• Synthesis of information on different gene therapy vectors and delivery systems.

Main Results:

• Gene therapy aims to correct or replace the defective gene responsible for RP.
• Multiple gene therapy approaches, including gene replacement and gene silencing, are being explored.
• Vector choice and delivery methods are critical for successful gene therapy in the retina.

Conclusions:

• Gene therapy represents a significant and evolving therapeutic frontier for autosomal dominant retinitis pigmentosa.
• Ongoing research holds promise for developing effective genetic treatments to preserve vision in RP patients.
• Understanding gene therapy mechanisms is crucial for advancing retinal disease therapies.